Insulet (NASDAQ:PODD) Hits New 12-Month Low – What’s Next?

Insulet Corporation (NASDAQ:PODD)’s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $141.02 and last traded at $143.4140, with a volume of 177186 shares traded. The stock had previously closed at $153.80.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: William Blair initiated coverage on Insulet with an Outperform rating, arguing that the valuation gap is hard to justify, which adds another bullish analyst view on the name.
• Positive Sentiment: RBC reaffirmed its Outperform rating and kept a $280 price target, signaling confidence in Insulet’s longer-term growth potential.
• Positive Sentiment: Zacks highlighted continued momentum in Omnipod 5, pointing to the company’s Q1 beat, raised 2026 outlook, and expanding global rollout as key growth drivers.
• Neutral Sentiment: Insulet announced it will present at the William Blair 46th Annual Growth Stock Conference on June 3, which is a routine investor-relations update and could attract attention but is not a direct business catalyst. Article: Insulet to Participate in William Blair 46th Annual Growth Stock Conference
• Neutral Sentiment: Citigroup cut its price target on Insulet to $165 from $175 while maintaining a Neutral rating, reflecting a more cautious near-term view despite still implying upside from current levels.
• Neutral Sentiment: Zacks also noted a Hold rating with a $163 target, suggesting analysts see decent growth but limited near-term room for a stronger rerating.
• Negative Sentiment: A U.S. appeals court overturned Insulet’s $452 million trade-secret verdict against EOFlow, removing a potential legal win and likely weighing on sentiment around the company’s competitive and litigation outlook. Article: US court overturns Insulet’s $452 mln insulin-pump trade secret verdict against EOFlow

Wall Street Analyst Weigh In

Several research firms have issued reports on PODD. Raymond James Financial lowered their price target on shares of Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Robert W. Baird lowered their price target on shares of Insulet from $360.00 to $248.00 in a report on Thursday, May 7th. Evercore lowered their price target on shares of Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price target on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Finally, William Blair began coverage on shares of Insulet in a report on Wednesday, May 20th. They set an “outperform” rating for the company. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $252.04.

Insulet Stock Down 2.3%

The firm has a market cap of $9.88 billion, a P/E ratio of 33.17, a price-to-earnings-growth ratio of 1.15 and a beta of 1.20. The stock’s 50 day simple moving average is $185.26 and its 200 day simple moving average is $246.01. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts anticipate that Insulet Corporation will post 6.43 EPS for the current year.

Hedge Funds Weigh In On Insulet

Several institutional investors have recently added to or reduced their stakes in the stock. Avidity Partners Management LP bought a new position in Insulet during the first quarter valued at about $2,098,000. Glenmede Trust Co. NA increased its holdings in Insulet by 6.5% in the 1st quarter. Glenmede Trust Co. NA now owns 2,717 shares of the medical instruments supplier’s stock worth $570,000 after acquiring an additional 166 shares during the last quarter. Essential Partners LLC increased its holdings in Insulet by 9,980.0% in the 1st quarter. Essential Partners LLC now owns 504 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 499 shares during the last quarter. Western Wealth Management LLC purchased a new stake in Insulet in the 1st quarter worth about $80,000. Finally, Edgestream Partners L.P. boosted its position in Insulet by 131.1% during the first quarter. Edgestream Partners L.P. now owns 21,645 shares of the medical instruments supplier’s stock worth $4,542,000 after purchasing an additional 12,277 shares during the period.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.